METHODS: Twenty children diagnosed with ADHD, who did not receive any medication for the preceding month, were randomised to receive the 8-week tablet-based BCI intervention either in the clinic or at home. Those in the home intervention group received instructions before commencing the program and got reminders if they were lagging on the training sessions. The ADHD Rating Scale was completed by a blinded clinician at baseline and at week 8. Adverse events were monitored during any contact with the child throughout the trial and at week 8.
RESULTS: Children in both groups could complete the tablet-based intervention easily on their own with minimal support from the clinic therapist or their parents (at home). The intervention was safe with few reported adverse effects. Clinician-rated inattentive symptoms on the ADHD-Rating Scale reduced by 3.2 (SD 6.20) and 3.9 (SD 5.08) for the home-based and clinic-based groups respectively, suggesting that home-based intervention was comparable to clinic-based intervention.
CONCLUSIONS: This trial demonstrated that the tablet version of our BCI-based attention training program can be safely delivered to children in the comfort of their own home. Trial registration This trial is registered at clinicaltrials.gov as NCT01344044.
方法:20名被诊断患有多动症的儿童,上个月没有接受任何药物治疗的人,在诊所或家中随机接受为期8周的基于片剂的BCI干预。家庭干预组中的人在开始该计划之前收到了指示,如果他们在培训课程中滞后,则会收到提醒。ADHD评定量表由盲症临床医生在基线和第8周时完成。在整个试验期间和第8周,在与儿童的任何接触期间监测不良事件。
结果:两组儿童都可以在诊所治疗师或其父母(在家)的最小支持下,自己轻松完成基于平板电脑的干预。该干预措施是安全的,几乎没有报告的不良反应。对于家庭和诊所组,临床医生在ADHD评定量表上对注意力不集中的症状分别减少了3.2(SD6.20)和3.9(SD5.08),表明家庭干预与临床干预具有可比性.
结论:该试验表明,我们基于BCI的注意力训练计划的平板电脑版本可以在舒适的家中安全地交付给儿童。试验注册该试验在clinicaltrials.gov上注册为NCT01344044。